Examkin

Question

Difficulty: MediumInfectious Diseases

A 42-year-old man is evaluated in the hospital for ongoing management of right knee septic arthritis. He originally presented 3 days ago with an acutely painful, swollen right knee and a temperature of 38.8°C (101.8°F). Initial arthrocentesis revealed purulent synovial fluid with 95,000 leukocytes/mm³, and a Gram stain demonstrated Gram-positive cocci in clusters. He underwent prompt arthroscopic irrigation and debridement, and was empirically started on intravenous vancomycin. Today, the patient reports feeling much better, his knee pain has decreased, and he has been afebrile for 24 hours. Final synovial fluid cultures are positive for Staphylococcus aureus. Antimicrobial susceptibility testing shows that the isolate is resistant to penicillin but susceptible to oxacillin, cefazolin, clindamycin, and vancomycin. Which of the following is the most appropriate next step in the antibiotic management of this patient?

  1. Switch to intravenous cefazolinAnswer
  2. B
    Continue intravenous vancomycin
  3. C
    Switch to intravenous piperacillin-tazobactam
  4. D
    Switch to intravenous linezolid
  5. E
    Switch to intravenous daptomycin

Answer

Switch to intravenous cefazolin
The patient's synovial fluid cultures have finalized, revealing Methicillin-Susceptible Staphylococcus aureus (MSSA), as indicated by its susceptibility to oxacillin and cefazolin. In the setting of deep tissue infections or bacteremia caused by MSSA, targeted therapy with a beta-lactam antibiotic—such as intravenous cefazolin, nafcillin, or oxacillin—is the definitive treatment of choice. These agents offer superior and more rapid bactericidal activity, better tissue penetration, and lower rates of clinical failure compared to vancomycin. Transitioning the patient to intravenous cefazolin represents appropriate antimicrobial stewardship by de-escalating from a broad-spectrum empiric regimen to the most effective, targeted, narrow-spectrum agent.

Step-by-Step Solution

1
Interpret the final culture and susceptibility results.
The pathogen is identified as Methicillin-Susceptible Staphylococcus aureus (MSSA) because it is susceptible to oxacillin and cefazolin.
Accurate identification of the pathogen's resistance profile is essential for tailoring definitive antibiotic therapy.
2
Apply principles of antimicrobial stewardship to the current empiric regimen.
The current regimen of intravenous vancomycin must be evaluated against the targeted susceptibility profile.
Empiric broad-spectrum therapy should be de-escalated to the narrowest, most effective targeted agent once cultures finalize.
3
Select the optimal targeted therapy for an invasive MSSA infection.
Intravenous cefazolin (or an anti-staphylococcal penicillin) is selected over continuing vancomycin or using other broad-spectrum agents.
Beta-lactams exhibit more rapid bactericidal activity and better clinical outcomes than vancomycin for MSSA infections.

Key Concept

De-escalation of broad-spectrum empiric coverage (e.g., vancomycin) to a targeted, narrow-spectrum beta-lactam (e.g., cefazolin) is the standard of care for invasive Methicillin-Susceptible Staphylococcus aureus (MSSA) infections.
Rate this question

Topics

Infectious Diseases

More questions from this topic